KCAS Bioanalytical and Biomarker Services

Expertise on using Hybrid LC-MS versus LBA for bioanalytical analysis.

Bioanalytical Methods to Optimize Drug Development: Hybrid LC-MS vs LBA

Selecting the right bioanalytical method to support qualitative and quantitative analysis requires flexibility and expertise from a CRO equipped to adapt to industry advancements.

Understand when to use LC-MS, LBA or both.

Learn why keeping LBA and Hybrid LC-MS in the forefront of your studies can result in big benefits.

Understand the best method to optimize your drug development outcomes.

See the entire 45-minute deep-dive broken into an 11-part video series, 

Videos

Drs Dawn Dufield and Dominic Warrino, KCAS Bioanalytical and Biomarker Services, share expertise on using Hybrid LC-MS versus LBA for bioanalytical analysis.

https://www.pharmtech.com/pt_w/addressing_challenges

Bioanalytical liquid chromatography­–mass spectrometry (LC–MS) for small molecules is often referred to as a routine technology. That perception may be true for many drugs, but as pharmaceutical companies move into new areas, more projects may present challenges in at least part of their scope, such as drug moiety, the matrices being assessed, the need for biomarker assessment, or high sensitivity requirements.

The challenge for bioanalytical service providers is to develop LC-MS assays to address these challenges and provide resulting methods that are robust and reliable enough to allow hand off to additional teams to support extensive sample analysis.

Develop knowledge of the factors that present analytical challenges when developing bioanalytical methodologies

Gain insight into strategies for dealing with challenging analytes, matrices, and assay limitations

Review case studies presenting experiences with solving challenging LC-MS/MS assays and translating the solution to a production

John Perkins, PhD, Senior Scientific Officer, KCAS

: Tuesday November 10, 2020 at 11am EST| 8am PST| 4pm CET| 5pm CET

On demand available after final airing until Nov. 10, 2021

Webcasts

***Live: Tuesday November 10, 2020 at 11am EST| 8am PST| 4pm CET| 5pm CET***Sometimes in bioanalysis, solving the fundamental challenge of developing an assay isn’t enough. The webcast will review strategies for solving scientifically challenging problems and providing assays that are robust and reproducible during routine sample analysis.*** On demand available after final airing until Nov. 10, 2021.***


Addressing the Challenges of Complex Analytes and Matrices in Preparation for Routine Sample Analysis 


	There has been concern amongst industry veterans that this pandemic and potential slowdown would follow the pattern of the recession in the last decade. However, the pharmaceutical industry is at the forefront of dealing with the challenges set by coronavirus and there has been considerable pharmaceutical company activity outside of the core drug development process. This presentation will provide an overview of recent developments in the pharmaceutical and bioanalytical industries outside of what is being done to address COVID-19. We will also include case studies looking at the scientific challenges that KCAS continues to see on a daily basis. 

		Public opinion of pharma – where it stands now

		Case studies examining scientific challenges KCAS continues to see on a daily basis

		Provide an overview of recent developments in the pharmaceutical and bioanalytical industries outside of what is being done to address COVID-19

		What it means to shift focus back to “business as usual” and the promising evidence we have that unlike 2008 business will continue

		Examine case studies looking at the scientific challenges that KCAS continues to see on a daily basis.

 John Perkins, PhD, Senior Scientific Officer, KCAS

	Dominic Warrino, PhD, Senior Scientific Officer, KCAS

Friday, May 29, 2020 at 11am EDT |  8am PDT | 4pm BST | 5pm CEST

	On demand available after airing until May 29, 2021.

Dominic Warrino and John Perkins of KCAS will provide an overview of recent developments in the pharmaceutical and bioanalytical industries outside of what is being done to address COVID-19. They will also examine case studies looking at the scientific challenges that KCAS continues to see on a daily basis.

Live: Friday, May 29, 2020 at 11am EDT |  8am PDT | 4pm BS T| 5pm CEST

On demand available after airing until May 29, 2020

Register free

KCAS Bioanalytical and Biomarker Services

Articles